For instance, in Ontario, Canada, the introduction of a policy aligning BGTS quantity limits with clinical guidelines resulted in a substantial and lasting change in utilization patterns, generating nearly USD 24 million (90.0 million Saudi Riyals) in savings within one year, primarily among individuals with diabetes not using insulin [18]. This evidence concerns the gene INS and diabetes mellitus.